Predicting drug sensitivity profiles from genotypes is a major challenge in personalized medicine. Machine learning and deep neural network methods have shown promise in addressing this challenge, but the "black-box" nature of these methods precludes a mechanistic understanding of how and which genomic and proteomic features contribute to the observed drug sensitivity profiles. Here we provide a combination of statistical and neural network framework that not only estimates drug IC 50 in cancer cell lines with high accuracy (R 2 = 0.861 and RMSE = 0.818) but also identifies features contributing to the accuracy, thereby enhancing explainability. Our framework, termed QSMART, uses a multi-component approach that includes (1) collecting drug fingerprints, cancer cell line's multi-omics features, and drug responses, (2) testing the statistical significance of interaction terms, (3) selecting features by Lasso with Bayesian information criterion, and (4) using neural networks to predict drug response. We evaluate the contribution of each of these components and use a case study to explain the biological relevance of several selected features to protein kinase inhibitor response in non-small cell lung cancer cells. Specifically, we illustrate how interaction terms that capture associations between drugs and mutant kinases quantitatively contribute to the response of two EGFR inhibitors (afatinib and lapatinib) in non-small cell lung cancer cells. Although we have tested QSMART on protein kinase inhibitors, it can be extended across the proteome to investigate the complex relationships connecting genotypes and drug sensitivity profiles. Introduction 1 Protein kinases are a class of signaling proteins, greatly valued as therapeutic targets for 2 their key roles in human diseases, such as cancer [1]. For decades, chemotherapy has 3 served as part of a standard set of cancer treatments; however, the resistance of cancer 4 cells to chemotherapy is still a major clinical challenge [2]. Mutations in protein kinase 5 are known to play important roles not only in drug resistance [3] but also in drug 6 sensitivity [4]. Depending on the structural location, mutations can have varying 7 impacts on drug sensitivity. For example, non-small cell lung cancer (NSCLC) cells 8 December 28, 2019 1/25 harboring either the EGFR T790M or L858R mutation respectively leads to resistance 9 or hypersensitivity to the cancer drug gefitinib [5, 6], while those with EGFR 10 T790M/L858R double mutant are only resistant to gefitinib [7]. As mutations impact 11 the efficacy of different cancer drugs, there is a need to incorporate structural 12 knowledge in drug response prediction methods. 13 To facilitate the understanding of the molecular mechanisms that cause drug 14 sensitivity and drug resistance in cancer cells, the Genomics of Drug Sensitivity in 15 Cancer (GDSC) Project [8] recently screened the drug responses of 266 anti-cancer 16 drugs against ∼1,000 human cancer cell lines and provided the largest publicly available 17 drug response dataset. Moreover, to broaden the pharmacologic annotation for human 18 cancers, the Cancer Cell Line Encyclopedia [9] (CCLE) provided pharmacologic profiles 19 for 24 drugs across 504 cancer cell lines. By utilizing these datasets, several prediction 20 models were built to pursue a more accurate drug response estimation by different types 21 of approaches, from traditional statistical models, network-based models, to the recent 22 machine learning methods and state-of-the-art neural networks (Table 1). These 23 approaches include (1) statistical models: MANOVA [10] and generalized linear models 24 (regularization: ridge [11-14], elastic net [11-13, 15], Lasso [11-13], and mixture [16]), (2) 25 network-based models [17-24], (3) random forests [25, 26], (4) support vector machine 26 (SVM) [21, 27, 28] and other kernelized methods [29-31], and (5) neural networks: 27 artificial neural network (ANN) [32], convolutional neural network (CNN) [33-35], 28 recurrent neural network (RNN) [35], and other deep neural networks (DNN) [36, 37].
Menden et al. [32] ANN (RF) MUT, CNV 8-fold CV R 2 = 0.72 2014.03.03 Geeleher et al. [11] GLM EXP LOOCV AUC = 0.81 2015.01.01 Jang et al. [12] GLM (PLS, SVM, PCA, RF) MUT, EXP, CNV, CLS 5-fold CV r = ∼0.5 2015.06. 30 Dong et al. [27] SVM EXP 10-fold CV Accuracy = ∼0.8 2015.09. 29 Zhang et al. [17] Network (EN) EXP LOOCV r = 0.6 2016.03. 31 Gupta et al. [28] SVM MUT, EXP, CNV LOOCV r = 0.78 2016.09.01 Ammad-ud-din et al. [29] Kernel (GLM) PWY 5-fold CV ρ = ∼0.22 2016.12. 28 Nguyen et al. [10] MANOVA (RF) EXP 10-fold CV MCC = 0.18 2017.01.09 Stanfield et al. [18] Network (Kernel) MUT, PPI LOOCV AUC = 0.881 2017.07. 15 Ammad-ud-din et al. [13] GLM (PLS, SGL, RF, SVM) EXP, PWY LOOCV ρ = 0.375 2017.08. 28 Geeleher et al. [14] Ridge EXP 10-fold CV ρ = 0.48 2017.09. 12 Rahman et al. [25] RF EXP 3-fold CV AUC = ∼0.3 2017.11. 13 Ding et al. [36] DNN (EN, SVM) MUT, EXP, CNV 25-fold CV AUC = 0.87 2018.03.08 He et al. [30] Kernel (EN, Ridge, RF) EXP 3-fold CV Precision = ∼0.35 2018.06. 11 Chang et al. [33] CNN (RF, SVM) SNP 5% leave-out R 2 = 0.843 2018.07.01 Cichonska et al. [31] Kernel SNP, MET, EXP, CNV 10-fold CV r = 0.858 2018.09.14 Le et al. [19] Network (Kernel) MUT, EXP 5-fold CV r = 0.804 2018.09.14 Juan-Blanco et al. [20] Network MUT, EXP LOOCV AUC = ∼0.72 2018.10.10 Yang et al. [21] Network + SVM (Kernel) MUT, MET, CNV, PPI 5-fold CV AUC = 0.788 2018.12.07 Liu et al. [22] Network EXP 10-fold CV r = 0.73 2019.01. 22 Wei et al. [23] Network EXP LOOCV r = 0.63 2019.01. 31 Wang et al. [15] EN EXP, PWY 10-fold CV MSE = ∼2.8 2019.01. 31 Chiu et al. [37] DNN (LR, SVM, PCA) MUT, EXP 10% leave-out r = ∼0.86 2019.02. 27 Li et al. [16] Mixture (GLM, RF) EXP 20% leave-out r = 0.882 2019.07. 11 Lind et al. [26] RF (SVM, ANN) MUT 5-fold CV r = 0.86 2019.07. 29 Liu et al. [34] CNN (ANN) MUT, CNV 10% leave-out R 2 = 0.826 2019. 10 . 16 Manica et al. [35] CNN + RNN (RF, SVM) EXP, CNV, PPI 5-fold CV R 2 = 0.86 2019.11.04 Oskooei et al. [24] Network (RF, LR) EXP, PPI 30-fold CV r = ∼0.9 Fig 1. The framework of using the QSMART model with neural networks to predict protein kinase inhibitor response in cancer cell lines. Four main components of this framework: (1) drug features, cancer cell line features, and drug responses, (2) statistics tests for interaction terms, (3) a feature selection method for identifying highly informative features, and (4) a machine learning method for predicting drug response.
sub-dataset. The overall prediction performance of our proposed framework and the 76 evaluation of each component are described below. 77 Overall performance of QSMART model with neural networks 78 For each cancer-centric model, Table 2 summarizes the number of PKI responses, the 79 total number of features (including drug features, cancer cell line features, and 80 interaction terms), the number of nodes in the first and second hidden layers of neural 81 networks, and prediction performance (R 2 ). Additional measurements of prediction 82 performance (RMSE and AUC), cancer cell line features at seven feature levels, 83 interaction terms, and training iterations are shown in S1 Table. By using the 84 QSMART model with neural networks, we can predict the PKI response in 23 cancer 85 types with accuracies ranging from R 2 = 0.805 to 0.880. Fig 2a presents IC 50 vs. 86 predicted IC 50 plot for all types of cancer cell lines (overall RMSE = 0.818 and R 2 = 87 0.861, which means these prediction models can explain 86% of the variation in PKI 88 responses). Although we designed three types of neural network architectures in this 89 study: single-layer, double-layer, and complex-double-layer (see Materials and methods), 90 we found that the prediction models for all the 23 cancer types can achieve R 2 > 0.8 by 91 using either single-layer or double-layer architecture. Based on Occam's razor The best performance for each cancer type is highlighted in bold. The performance of each machine learning method, except for ANOVA and MCA [35] , is based on 10-fold cross-validation. The performance of MCA is based on its prediction for PKI response (S1 Data). AG: autonomic ganglia; ANOVA: analysis of variance; CNS: central nervous system; DxM: drug-mutation interaction term; MCA: multiscale convolutional attentive; NN: neural networks; NSCLC: non-small cell lung cancer; R 2 : coefficient of determination; RF: random forests; SVM: support vector machine; UAT: upper aerodigestive tract; #IC 50 : the number of drug responses; #Nodes: the number of nodes in the first and second hidden layers of neural networks.
models. The overall residual plot (Fig 2b) shows that there is no specific U shape, 95 inverted U shape, or funnel shape, which means our prediction models need no more 96 higher-order features to capture the variation of drug responses (S1 Fig shows residual threshold used in a previous study [33] (IC 50 = -2), we set multiple thresholds (-4, -3, -2, 101 -1, and 0) and averaged the results to avoid overestimating the prediction performance. 102 The resulting ROC curves for 23 cancer types and the overall curve are shown in Fig 2c . 103 The overall AUC is 0.981 and comparable to a recent deep neural network-based 104 study [33] (AUC > 0.98). AUC for each cancer-centric model is available in S1 Table. 105
Contribution of different feature categories 106
To roughly estimate the contribution of different feature types to the prediction 107 accuracy, we split the features into three different categories: drug features, cancer cell 108 line features, and interaction terms. We used the same neural network architecture (the 109 number of nodes in the first and second hidden layers) in each cancer-centric model, and 110 then built prediction models by using the split feature sets. Across the 23 cancer types, 111 this experiment showed that using drug features alone to predict PKI response Prediction performances of different datasets and different prediction models. Wilcoxon signed-rank test is performed to compare prediction performances and the p-value is shown in each box plot. (a) Comparison between actual IC 50 (x-axis) and the IC 50 predicted by using QSMART with neural networks across all cancer types (y-axis). The hexbin plot is drawn by an R package "ggpubr" [40] . A fitted regression line is shown. (b) Residual analysis for the models using QSMART with neural networks across all cancer types. X-axis: predicted IC 50 ; y-axis: residuals, defined as actual IC 50 minus predicted IC 50 . (c) AUC curves of 23 cancer-centric models and an overall AUC. (d) The prediction performances of split QSMART models. (e) The prediction performances of using different datasets and different feature selection methods. GF: genomics fingerprints; NoDM: no drug-mutation interaction terms; NoX: no interaction terms; Rand: random selection; Rand10X: randomly select 10 times the number of features in the QSMART model. (f) The prediction performances of using different statistical or machine learning methods. NN: neural networks; RF: random forests; SVM: support vector machine; ANOVA: analysis of variance; MCA: multiscale convolutional attentive.
selected drug features being more than those of the other two feature categories, the 117 main reason was that the drug features were more informative in cancer-centric models. 118 Since the entire training dataset was split into 23 cancer-centric datasets, the similarity 119 among cancer cell lines in one dataset was higher than the similarity among PKIs and 120 thus the drug features had higher variation and higher entropy.
121
Assuming that the features from different categories in a full model are independent 122 and can explain the variation of drug response independently, the summation of the 123 prediction performances of split models (the R 2 SSP in Table 3 ) would ideally be the 124 upper limit of a full model. However, Table 3 shows that the prediction performances 125 R 2 Full are even higher than R 2 SSP for 14 cancer types, which implies that the 
Contribution of interaction terms in the QSMART model 153
To evaluate the second component of the framework in this study -F-test for identifying 154 significant interaction terms -we performed two experiments: removing drug-mutation 155 interaction terms and removing all interaction terms. We utilized the feature selection 156 method to prioritize all input features, selected the same total number of features in the 157 original models shown in Table 2 , and then used the same neural network architectures 158 to train the new models. The results of these two experiments are shown in S3 Table   159 and S4 Table, QSMART models, we found that the prediction models of some cancer types, such as 164 upper aerodigestive tract and breast, achieved higher performance without using any 165 interaction terms. We conjectured that it was because some informative high-order 166 interactions were captured inside the neural network black box and thus compensated 167 the lack of interaction terms in the input layer. However, using neural networks cannot 168 guarantee that these informative but unexplainable high-order interactions will be 169 captured under the limited number of samples and the training iteration we used. This 170 fact is reflected in Fig 2e, which shows that the prediction performance is variable when 171 the drug-mutation interaction terms are not used (R 2 = 0.653 to 0.892) or all the 172 interaction terms are not used (R 2 = 0.581 to 0.912). In this paragraph, we validate 173 that adding interaction terms significantly contributes to PKI response prediction; in a 174 non-small cell lung cancer case study described below, we will illustrate how the 175 statistical interaction terms are interpreted as potential physical drug-target 176 interactions and thus increase the explainability of prediction models.
177
Feature selection method: Lasso with BIC control 178 We next evaluated the feature selection methods. Since building neural networks using 179 all the features from the first two components of the framework cannot be finished 180 within a reasonable amount of time, instead of removing the third component of the 181 framework, we randomly selected the same number of features in the original model for 182 each cancer type shown in Table 2 . Then, we trained a new neural network model with 183 the same architecture for each cancer type. For each cancer type, the number of 184 randomly selected features along with prediction performances are shown in S5 Table. 185 It is not surprising that the prediction performances dropped to R 2 = 0.031 to 0.138 186 (overall R 2 = 0.125). To further evaluate the feature selection method we used, we 187 increased the number of randomly selected features to 10 times the original number.
188
The performances increased to R 2 = 0.052 to 0.707 (S6 Table; overall R 2 = 0.378).
189
Nevertheless, these performances are significantly lower than those of the original 190 models that utilize Lasso with BIC control (Fig 2e) . Furthermore, based on the feature sets used to validate the contribution of previous 201 components in the framework, neural networks also outperformed random forests, SVM, 202 and Lasso regression (S2 Table-S6 Table) . A previous study [33] also showed that neural 203 networks outperformed random forests and SVM (R 2 = 0.843, 0.698, and 0.562 for 204 DNN, random forests, and SVM, respectively) in drug response prediction. Interestingly, 205 neural network was only slightly better than Lasso in overall performance when 206 randomly selected features were used as inputs (R 2 = 0.125 vs. 0.116, p-value = 0.015, 207
Wilcoxon signed-rank test).
208
In addition to the three commonly used machine learning approaches, we compared 209 our models with two-way ANOVA analysis and MCA [35] . Two-way ANOVA analysis 210 was applied to assess the ability of two factors -drug and cancer cell line -to explain 211 the variation of drug response. Drug IDs and cancer cell line IDs represented different 212 levels of drug and cancer cell line, respectively. The result of two-way ANOVA showed 213 that these two factors could explain 67.2% to 80.9% of the drug response variation in 214 different cancer types ( Table 2 ; overall R 2 = 0.755). Compared to ANOVA and MCA, 215 using the QSMART model with neural networks had significantly higher ability to 216 explain the PKI response variation for 23 cancer types (p-value < 1.4e-05 and p-value = 217 0.00057, respectively; Fig 2f) .
218
Case study: non-small cell lung cancer 219 We next evaluated the contribution of different features in drug response prediction General Hospital showed lower drug sensitivity (higher IC 50 value) than those from the 230 Wellcome Sanger Institute in the NSCLC dataset (average actual IC 50 = 2.88 vs. 2.41). 231 To investigate these experimental batch effects, we increased one unit to this feature and 232 held other features constant. Although holding other features constant is not possible in 233 reality, from the mathematical point of view, the result showed that if we replace 0 with 234 1 for From Sanger, the average IC 50 predicted by our pre-trained model will reduce 0.65 235 (average predicted IC 50 = 2.87 vs. 2.22, S2 Data). Interestingly, this feature was 236 selected not only in the NSCLC model but also in other 22 cancer-centric models, 237 meaning the batch effects were significant across the assays done by these two institutes. 238
Biological processes interaction 239 "GO 0030324 X GO 0048675". This feature represents the multiplication of the number 240 of mutations perturbing the biological process "lung development" (Gene Ontology ID: 241 December 28, 2019 9/25 GO:0030324) and the number of mutations perturbing "axon extension" (Gene
242
Ontology ID: GO:0048675). Axon initiation, extension, and guidance are known to play 243 important roles in cancer invasion and metastasis [43] . In the NSCLC dataset, there are 244 eight cell lines with mutations in protein kinases associated with axon extension; among 245 them, NCI-H1944 and NCI-H2030 are from patients with metastatic NSCLC. On 246 average, the NSCLC cell lines with this interaction showed higher PKI responses than 247 those without this interaction (average actual IC 50 = 4.32 vs. 2.69) and those involved 248 in "lung development" or "axon extension" alone (average actual IC 50 = 3.20 or 2.07, 249 respectively). Based on our prediction model, every unit increase in this interaction 250 term is associated with a 0.45 unit increase in IC 50 on average (average predicted IC 50 251 = 2.73 vs. 3.18). Table) . MAP4K4, one of the genes involved in the apoptosis 260 signaling pathway, is an emerging therapeutic target in cancer [45] , and its 261 over-expression is a prognostic factor for lung adenocarcinoma [46] . MAP4K4 262 expression is up-regulated upon binding by p53, and it will then activate the JNK 263 signaling pathway to drive apoptosis [47] . In the NSCLC dataset, when the expression 264 of MAP4K4-TP53 interaction increases, average IC 50 is slightly decreased (Pearson 265 correlation = -0.10); in our pre-trained PKI response prediction model, every unit of 266 gene expression level increase in MAP4K4-TP53 PPI is associated with 0.012 unit 267 decrease in IC 50 on average (average predicted IC 50 = 2.727 vs. 2.715).
268
CDK13, an understudied protein kinase defined by NIH Illuminating the Druggable 269 Genome (IDG) program [48] (S3 Data, last updated on June 11, 2019), participates in a 270 4-clique PPI module in the TP53-centric subnetwork (Fig 3) . Its three PPIs in this 271 module are all the features of the NSCLC-specific model. One of CDK13's PPI partners, 272 AKAP4, is a biomarker for NSCLC, and its expression increase was associated with 273 tumor stage [49] . In addition to NSCLC, AKAP4 is also a potential therapeutic target 274 of colorectal cancer [50] and ovarian cancer [51] , and it regulates the expression of the 275 CDK family. In the NSCLC dataset, the expression of CDK13-AKAP4 interaction had 276 a weak positive correlation with IC 50 (Pearson correlation = 0.07); in the prediction 277 model, every unit of gene expression level increase in CDK13-AKAP4 PPI is associated 278 with 0.017 unit increase in IC 50 on average (average predicted IC 50 = 2.727 vs. 2.744). 279
Drug-mutation interaction 280
In total, there are 47 drug-mutation interaction terms in the NSCLC model, and they . Notably, the L858R mutation can be accomodated in the active conformation 293 of EGFR, but not in the inactive state due to steric hindrance [54] . 294 An interaction analysis (Fig 4d) shows that the mutated residues involving charge 295 difference at PKA 187 have significant interaction (p-value = 0.043, F-test) with 296 Fingerprint 791, a drug substructure "NC1CCC(N)CC1" of afatinib). Based on our 297 prediction model, every unit increase in the interaction term 298 "PKA 187 CHA X Fingerprint 791", an interaction term with one of the highest impact 299 on IC 50 among all the drug-mutation interaction terms in the model (S8 Table) , is 300 associated with a 0.46 unit decrease in IC 50 on average (average predicted IC 50 = 2.73 301 vs. 2.27). Another interaction analysis (Fig 4e) shows that the mutated residues 302 involving volume difference at PKA 187 have significant interaction (p-value = 0.035, 303 F-test) with Fingerprint 826 (a drug substructure "OC1C(N)CCCC1" of afatinib).
304
Every unit increase in "PKA 187 VOL X Fingerprint 826" is associated with a 0.01 305 unit decrease in IC 50 on average (average predicted IC 50 = 2.73 vs. 2.72). Since 306 lapatinib lacks both substructures Fingerprint 791 and Fingerprint 826, we speculate 307 that mutant EGFR in NSCLC cells with a larger, positively charged mutation at 308 PKA 187 are resistant to lapatinib (the blue lines in Fig 4d and Fig 4e) . In this study, we propose a PKI response prediction framework to accurately estimate 311 IC 50 values with a more explainable AI model. This framework includes four components: (1) drug features, cancer cell line's multi-omics data, and PKI responses, 313 (2) statistical tests for capturing interaction effects, (3) feature selection, and (4) neural 314 networks. We validate the contribution of each component, showed high prediction 315 performances, and used NSCLC dataset as a case study to explain several features. We 316 systematically investigate the contributions of various interaction effects (such as 317 protein-protein interactions, pathway-pathway interactions, and drug-mutation 318 relationships) to drug response prediction.
319
The intrinsic limitation of drug response prediction is the unexplainable variation of 320 drug response caused by different assays and experimental conditions. Currently, GDSC 321 and CCLE are the two main sources for studying cancer drug response. Several previous 322 studies about predicting drug response used data not only from GDSC but also from 323 CCLE ( Table 1) . However, a previous study [20] pointed out that although GDSC and 324 CCLE datasets shared 343 cancer cell lines and 15 drugs, the drug responses from these 325 two datasets were poorly correlated. Thus, we chose to only use a single source in this 326 study to minimize the unexplainable effect from different experimental environments.
327
Nevertheless, this situation impeded us from finding appropriate independent testing set 328 outside the GDSC data. Even though the drug response data we used were only from 329 GDSC, the feature selection process showed that the drug feature "From Sanger" was 330 selected for all the 23 cancer-centric prediction models, meaning the batch effects were 331 significant across the assays. While our studies were underway, we noticed that GDSC 332 8.0 was released. Compared with release 7.0, it contains 160 thousand more drug 333 responses. However, this dramatic increase did not provide us a syncretic testing set 334 since the old drug response dataset (called GDSC1 in release 8.0) and the new drug 335 response dataset (called GDSC2) were generated based on different types of assays.
336
Although the drug responses measured by different assays seem to have high correlation 337 (R = 0.838 in Pearson correlation coefficient), unfortunately, it implies that even if we 338 train a perfect model for GDSC1, the performance of predicting the drug responses in 339 GDSC2 as an independent testing set would only be R 2 = 0.702 ( S3 Fig panel a) . 340 Moreover, if we only focus on PKI responses between the two datasets, the correlation is 341 reduced to 0.774 and R 2 = 0.599 ( S3 Fig panel b ). Furthermore, if we use our 342 pre-trained models to predict the PKI response in GDSC2, the overall performance 343 drops to R 2 = 0.556 ( S3 Fig panel c) . 344 In the case study, we illustrated the possibility of interpreting statistical interaction 345 terms into potential physical interactions. When we investigated the contribution of 346 protein-protein interactions to drug response prediction, the original purpose of utilizing 347 biological knowledge (such as known PPIs from STRING [55] ) was to narrow down the 348 huge search space (a matrix of 30,000 proteins by 30,000 proteins). Consequently, this 349 additional information also helped us explain the biological role of these statistical 350 interaction terms with preliminary evidence. On the contrary, when we investigated the 351 contribution of drug-mutation relationships to drug response prediction, we explored all 352 the interactions between drug features and the mutations at reference PKA positions.
353
Although restricting the mutations to be in the region around ATP-binding pocket 354 (from PKA 47 to PKA 188, defined by the Kinase-Ligand Interaction Fingerprints and 355 Structures (KLIFS) database [56] ) could increase the probability of finding physical 356 interactions among those statistical interaction terms, we will lose the opportunity to 357 explore the potential interactions between PKIs and the allosteric binding sites outside 358 the ATP-binding pocket.
359
In conclusion, by integrating multi-omics data, utilizing the innovative QSMART 360 model, and employing neural networks, we not only can accurately predict PKI 361 responses in cancer cell lines but also increase the explainability behind our prediction 362 models. Compared to traditional QSAR models, the QSMART model proposed in this 363 study further introduces different types of interaction terms. While we demonstrate our 364 model in protein kinase binding, the QSMART model can be applied to other protein 365 families, such as G protein-coupled receptors (GPCRs) and ion channels. Moreover, the 366 concept of QSMART model can also be broadly applied to other types of interactions, 367 such as the protein-protein interaction that we had demonstrated, drug-drug interaction, 368 glycosyltransferase-donor analog interaction, gene-environment interaction, and 369 agent-host interaction.
370

Materials and methods
371
Protein kinase inhibitor 372 We define small-molecule (molecular weight < 900 daltons) protein kinase inhibitors 373 (PKIs) in GDSC (release 7.0) [8] from a variety of publicly available, manually curated 374 drug-target databases, and experimental data. The list of human protein kinases in this 375 study is defined by ProKinO (version 2.0) [57] . Drug-kinase associations were extracted 376 from DrugBank (version 5.1.0) [58] , Therapeutic Target Database (TTD, last accessed 377 on September 15th, 2017) [59] , Pharos (last accessed on May 15th, 2018) [60] , and 378 LINCS Data Portal (last accessed on May 15th, 2018) [61] . We define a drug as a PKI 379 if it is annotated as an "inhibitor", "antagonist", or "suppressor" in the drug-kinase Descriptor Calculator GUI (version 1.4.6) [63] generated 881 PubChem fingerprints and 400 286 chemical descriptors including constitutional, topological, electronic, geometric, and 401 bridge descriptors. Observing high multicollinearity within features, we removed 402 redundant features and implemented the variance inflation factor (VIF) criterion [64] to 403 reduce multicollinearity (for more details, see the Feature screening section below).
404
After filtering, 92 PubChem fingerprints and 0 chemical descriptors remained.
405
To compare our prediction performances with those in a previous study [33] , we used 406 the same methods to generate (1) fingerprints, (2) extended fingerprints, and (3) 407 graph-only fingerprints by PaDEL-descriptor (version 2.21) [41] for each drug. In total, 408 there are 3,072 binary descriptors as drug features in the compared training sets. The 409 relatively large, unfiltered set of drug features are only used for comparison purposes in 410 our study.
411
Cancer cell line features 412
Using mutation profiles for each cancer cell line sample provided by COSMIC Cell Lines 413 Project (v87) [42] , we incorporate 7 categories of multi-omics data to quantify the 414 differences between wild type and mutant protein kinases: (1) residue-level: reference Cellosaurus [70] ).
427
The formula for generating all cancer cell line features is shown in S9 Table. 428 Residue-level features of a cancer cell line were extracted from COSMIC mutants 429 labeled as "Substitution -Missense". These features were then calculated if the 430 mutation position could be aligned to the reference PKA position. This choice is based 431 on an assumption that, for all protein kinases, mutations at equivalent positions will 432 have similar effects on drug response. We further used two different types of weights, 433 conservation score (KinView [71] with Jensen-Shannon divergence calculation [72] ) and 434 gene expression, to estimate the different effects of the same mutant type aligned to the 435 same PKA position from different protein kinases. 
where β 0 is the intercept, β 1i and β 2j represent the coefficients of the ith drug feature 449 D i and the jth cancer cell line feature C j , and is the error term.
450
Because the residue-level features of a cancer cell line represent the mutation status 451 in the reference PKA structure and we are interested in investigating drug-mutation relationships, we introduced drug-mutation interaction terms into the model:
where β 3ik is the coefficient of the interaction term formed by the ith drug feature D i incorporate all cancer cell line features as part of interaction terms. For example, we did 459 not consider the interaction between a substructure "Fingerprint 1" and a biological 460 process "lung development" because it is unexplainable.
461
In addition to using all cancer cell line features, we further introduced more types of 462 interaction terms into the full QSMART model to capture the environment of a cancer 463 cell line:
where β 4p , β 5q , β 6r , and β 7s are the coefficients of the pth protein-protein interaction 465 P P I p , the qth reaction-reaction interaction RECx q , the rth pathway-pathway 466 interaction P W Y x r , and the sth biological processes interaction GOx s , respectively.
467
These four types of interaction terms are formed by all pairs of protein, reaction, 468 pathway, and biological process features, respectively. More details about interaction 469 terms are described below.
470
Interaction terms 471 Five types of interaction terms were introduced into the QSMART model: 472 drug-mutation interaction, protein-protein interaction, reaction-reaction interaction, 473 pathway-pathway interaction, and biological processes interaction. These interactions 474 were not necessarily physical interactions; instead, they were predictors that show 475 statistically significant contribution to explaining the variation of IC 50 values. For 476 drug-mutation interaction term, only the residues mapping to the reference PKA 477 structure were considered to form interactions with drugs. To reduce the search space, 478 prior biological knowledge was used to filter interactions with less biological relevance. 479 For protein-protein interaction (PPI), we retain PPIs with scores higher than 700 in the 480 STRING database [55] . Gene expression level was used as a weight for PPIs to roughly 481 represent the protein abundance in cancer cell lines. For reaction, pathway, and
Datasets 490
To reduce more potential sources of noise and bias, we further filter cancer cell lines 491 from the PKI response dataset if (1) their mutation profiles are not detected by 492 whole-genome sequencing,(2) they have less than 30 drug response entries, (3) their gene 493 expression profile is not available, or (4) their mutation site does not map to a residue 494 in the reference PKA position. The dataset was then split into 29 groups, stratified by 495 cancer primary site. Groups with less than 1,000 responses (adrenal gland, biliary tract, 496 placenta, prostate, salivary gland, small intestine, testis, and vulva) were excluded due 497 to low statistical power. "Haematopoietic and lymphoid tissue", the largest group, was 498 further divided into two subsets by primary histology: "haematopoietic neoplasm" and 499 "lymphoid neoplasm". For the case study, we collected cancer cell lines for the non-small 500 cell lung cancer (NSCLC) dataset from the lung cancer dataset if their histology subtype 501 is adenocarcinoma, non-small cell carcinoma, squamous cell carcinoma, large cell 502 carcinoma, giant cell carcinoma, or mixed adenosquamous carcinoma. Remaining lung 503 cancer cell samples were classified as "lung (others)". We created cancer type-centric 504 training sets by expanding the drug response dataset with drug features, cancer cell 505 lines features, and significant interaction terms. Categorical data in the training sets 506 were coded into dummy variables. As a result, we prepared 23 cancer type-centric 507 training sets. The number of PKI response for each cancer type is shown in Table 2 .
508
Feature screening 509
Observing high multicollinearity within the features in the first component of our 510 prediction framework (Fig 1) , we implemented the variance inflation factor (VIF) 511 criterion [64] to remove highly correlated features. For the multiple regression model 512 with f features, X i (i = 1, ..., f ), the VIF for the ith feature can be expressed by: implemented Lasso [75] with Bayesian information criterion (BIC) [76] by an R package 531 "HDeconometrics" [77] (the third component of our prediction framework in Fig 1) 532 because Lasso is appropriate for estimating coefficients in high-dimensional space [78] 533 and BIC provides an efficient approach to obtain the optimal lasso fit [79] . After feature 534 We built neural network models by using JMP ® [80] . We designed three types of neural 538 network architectures in this study: single-layer, double-layer, and complex-double-layer. 539 The numbers of hidden layer nodes follow the geometric pyramid rule [81] . Given N 540 input nodes, there are N 1/2 hidden nodes in a single-layer architecture. In a 541 double-layer architecture, there are N 2/3 and N 1/3 hidden nodes in the first and 542 second hidden layers, respectively. In a complex-double-layer architecture, there are N 543 and N 1/2 hidden nodes in the first and second hidden layers, respectively. The nodes 544 among the two layers are fully connected. Biases are introduced into the input and 545 hidden layers. The activation function of every node in the neural network is a 546 hyperbolic tangent function (TanH). Newton's method [82] is chosen as an optimizer by 547 JMP.
548
To avoid overfitting, we implement 10-fold cross-validation, early stopping, and 549 Lasso-style penalty function (absolute value penalty, i.e. L1 regularization [83] ). Based 550 on Occam's razor principle [39] , we started from a single-layer model for each cancer 551 type. If the performance (average R 2 of the intact validation sets across the 10 folds) is 552 less than a threshold 0.8 in 200 iterations, we increased the iteration to 300; if the 553 performance is still less than the threshold, we implemented a double-layer model for 554 200 iterations and so on until using a complex-double-layer model for 300 iterations. To 555 increase the reproducibility of this study, fixed random seeds were assigned and all the 556 codes for training and prediction models are available at 557 https://github.com/leon1003/QSMART/.
558
Other machine learning models 559 We compared neural networks with three other prediction algorithms with 10-fold 560 cross-validation: random forests [84] , support vector machine (SVM) [85] , and 561 Lasso [75] . Random forests were implemented by WEKA (version 3.8.3) [86] with 562 default settings ("maxDepth" = 0, "bagSizePercent" = 100). For each cancer type, the 563 number of iterations was decided based on the iterations used for each of the pre-trained 564 neural network models (200 or 300 iterations) shown in S1 Table. SVM was 565 implemented by the SMOreg function (SVM for regression) of WEKA with default 566 kernel ("PolyKernel") and optimizer ("RegSMOImproved") settings. Lasso was 567 implemented by an R package "glmnet" [87] with the default parameter setting for 568 Lasso regression (alpha = 1 and family = "gaussian"). Additionally, we also compared 569 our prediction models with two-way ANOVA analysis and MCA [35] . Because the 570 purpose of two-way ANOVA analysis implemented by R was to quantify how much two 571 factors (drug and cancer cell line) can explain the variation of drug response (adjusted 572 R 2 was used), the model used the drug and cancer cell line identifiers as inputs and did 573 not undergo 10-fold cross-validation. The performance of MCA shown in Table 2 is 574 based on its prediction for PKI response (details are available in S1 Data). 
